Hints and tips:
...dystrophy, a rare childhood wasting disease....
...In the biotech sector, Sarepta Therapeutics almost doubled earlier in the day after the US drugs regulator approved its treatment for duchenne muscular dystrophy, a rare and fatal childhood disorder....
...Glyn Edwards, chief executive of Summit, a UK company developing drugs to treat the childhood disease Duchenne muscular dystrophy, described it as “a big step forward”....
International Edition